Analysis of drug registration compliance and access in target markets

What to prepare

Input the drug type and target country/region, automatically identify the registration authority and path, generate a list of application materials and timeline, evaluate access risks and compliance recommendations, and output a structured access analysis report. Support API/finished drug preparations/biological products/Chinese patent medicines, covering FDA/EMA/NMPA/ANVISA/PMDA and other multi-national regulatory systems, and can be customized according to the registration purpose (marketing/clinical trials/raw material filing/generic ANDA). Example input: drug type (API/finished drug/biological product/Chinese patent medicine); target country/region (comma-separated multiple countries, such as the United States, Germany, Brazil), (optional: common name/code (no limit to leaving blank); registration purpose (marketing/clinical trial/raw material filing/generic ANDA, leave blank to default to marketing)).

Type of drug (API/finished drug/biological product/proprietary Chinese medicine)Required

Follow the field instructions to enter your content.

Common name/code name (no limit to leaving blank)Optional

Follow the field instructions to enter your content.

Target countries/regions (comma separated multiple countries, such as the United States, Germany, Brazil)Required

Follow the field instructions to enter your content.

Registration purpose (marketing/clinical trials/raw material filing/generic ANDA, leave blank to default to marketing)Optional

Follow the field instructions to enter your content.

Model (leave blank to use default)Optional

Follow the field instructions to enter your content.

Generation instructions

Each row is submitted as a separate task. Required fields are marked with *.